EVX-02 is under clinical development by Evaxion Biotech and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EVX-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EVX-02 overview
EVX-02 is under development for the treatment of resected melanoma. The drug candidate is a DNA vector which encodes for 13 predicted patient-specific neoantigens identified by proprietary AI platform PIONEER. The personalized vector is administrated together with poloxamer intramuscularly through needle injection or alone though PharmaJet jet injector.
See Also:
Evaxion Biotech overview
Evaxion Biotech ApS (Evaxion) is a clinical-stage biotech company that harnesses artificial intelligence (AI) to develop immunotherapies with improved efficiency to treat patients with unmet medical needs. Simulating the human immune system, it strives to develop predictive models to identify and develop customized and other next-generation immunotherapies. The company uses its proprietary AI technologies to decode the human immune system and develop immunotherapies for cancer, bacterial infections and viral infections. Evaxion obtained the pipeline products including personalized cancer immunotherapies and infectious diseases vaccines from its proprietary AI platforms, PIONEER, EDEN, RAVEN and ObsERV. These platforms use machine learning (ML) models of the immune system to identify novel disease targets and accelerate the drug development process, reducing timelines, costs, and attrition. Evaxion is headquartered in Copenhagen, Denmark.
For a complete picture of EVX-02’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
